Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010

Simon Faissner(St. Josef-Hospital), Ralf Gold(St. Josef-Hospital)

CNS Drugs

March 1, 2018

10.1007/s40263-018-0488-6

Cited by 80

Abstract

Related Papers

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

Robert J. Fox, David H. Miller, J. Theodore Phillips et al.|New England Journal of Medicine|2012|1.3k

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

Ralf A. Linker, De-Hyung Lee, Sarah Ryan et al.|Brain|2011|1.2k

Multiple Sclerosis: Current Knowledge and Future Outlook

Christian P. Kamm, Bernard M.J. Uitdehaag, Chris H. Polman|European Neurology|2014|1k

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

The CAMMS Trial Investigators|New England Journal of Medicine|2008|1k

Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice

David J. DiLillo, Yasuhito Hamaguchi, Yoshihiro Ueda et al.|The Journal of Immunology|2008|372